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P rocalcitonin (PCT) has been routinely measured in many patients since it was first shown to be a 
marker of sepsis in 1993 [1].  An increase in PCT starts 
before an increase in C-reactive protein (CRP),  and the 
PCT level is useful for the diagnosis of bacterial infec-
tion and sepsis and as an indicator of the severity and 
prognosis of systemic inflammatory diseases; it is also 
useful for determining the response to individual treat-
ment [2-7].  PCT is a precursor of calcitonin.  It is not 
produced in a healthy state but is produced by various 
tissues under septic conditions.  The serum PCT level is 
less than 0.1 ng/mL in a healthy state,  and a level higher 
than 0.5 ng/mL is indicative of sepsis [8-10].  However,  
serum PCT levels can be elevated in diseases other than 
bacterial infections,  and there have been some reports 
of nonbacterial induction of PCT,  such as the induction 
of PCT in patients with multiple organ failure and 
patients with severe trauma [2 , 11].
Since there are many patients with elevated levels of 
PCT due to nonbacterial causes,  the level of serum PCT 
is often used as a marker for the early detection of not 
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Various laboratory markers of inflammation are utilized in general practice,  but their clinical diagnostic signif-
icance is often ambiguous.  In the present study,  we determined the clinical significance of the examination of 
serum levels of procalcitonin (PCT) by comparing the PCT levels with the levels of other inflammatory mark-
ers,  based on a retrospective review of 332 PCT-positive patients,  including cases of bacterial infection 
(20.5%),  non-specific inflammation (20.8%),  neoplasm (9.9%),  connective tissue diseases (8.4%),  and 
non-bacterial infection (7.2%),  were analyzed.  The serum PCT level was highest in the bacterial infection group 
(1.94 ng/ml) followed by the non-specific inflammatory group (0.58 ng/ml) and neoplastic diseases group 
(0.34 ng/ml).  The serum PCT level was positively correlated with serum levels of C-reactive protein (rho= 0.62),  
soluble interleukin-2 receptor (sIL-2R; rho= 0.69),  and ferritin,  the plasma level of D-dimer,  and white blood 
cell count,  and negatively correlated with the serum albumin level (rho= −0.52),  hemoglobin concentration,  
and platelet count.  The serum PCT level showed a stronger positive correlation with the serum sIL-2R level 
than the other biomarkers.  The results suggest that an increased PCT level may indicate not only an infectious 
state but also a non-bacterial inflammatory condition in the diagnostic process in general practice.
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only bacterial infection but also many inflammatory 
and/or febrile disorders,  including fever of unknown 
origin (FUO),  in the clinical setting of general medi-
cine.  In this regard,  we have reported that the categori-
zation of patients with FUO and the gathering of infor-
mation on daily changes in the febrile condition and on 
abnormalities in serum electrolytes such as hyponatre-
mia are important for the differential diagnosis of vari-
ous inflammatory diseases [12 , 13].  However,  the 
clinical significance of PCT for the diagnosis of condi-
tions other than sepsis has not been established.
In this study,  we investigated the clinical signifi-
cance of serum levels of PCT measured in the process of 
diagnosing inflammatory disorders in order to deter-
mine whether the serum PCT level is useful in the field 
of general practice by examining the relationships 
between PCT levels and other related biomarkers.
Patients and Methods
Patients. We retrospectively analyzed the medi-
cal records of 359 patients who visited and were admit-
ted to the Department of General Medicine,  Okayama 
University Hospital during the period from January 
2015 to December 2017 and whose PCT levels were 
measured.  Of the 359 cases,  332 cases with PCT levels 
above the measurement sensitivity level were included 
for analysis.  The patients included 166 males (50%) and 
166 females (50%) with a mean age of 58.6 years (range,  
16-95 years).  Information on this study was provided 
on the website of our hospital and on a wall of our hos-
pital,  and a meeting point was provided for patients 
who wished to opt out.  The study protocol (#K-1808008) 
was approved by the Institutional Review Board of 
Okayama University Graduate School of Medicine,  
Dentistry,  and Pharmaceutical Sciences.
Laboratory examinations. Blood cell counts,  
including red blood cell,  white blood cell (WBC),  and 
platelet counts,  as well as hemoglobin concentration,  
serum levels of CRP,  albumin,  and ferritin,  and the 
plasma level of D-dimer were determined by an auto- 
analyzer system in the Central Laboratory of Okayama 
University Hospital.  The serum level of soluble inter-
leukin-2 receptor (sIL-2R) was measured by an enzyme 
immunoassay using a commercially available kit (BML,  
Kawagoe,  Japan).  The serum level of PCT was mea-
sured using an electrochemiluminescence immunoassay 
(ECLusys Brahms PCT (Roche Diagnostics,  Tokyo).  
All PCT levels were measured using the first sample 
obtained during the clinical course,  and the levels of 
other biomarkers were measured at the same time that 
PCT was measured.
Statistical analysis. The data were subjected to a 
Kruskal-Wallis test to determine significant differences 
between the groups.  If differences were detected by the 
Kruskal-Wallis test,  the Steel-Dwass post-hoc test was 
used to determine which subject differed.  The data 
were also analyzed by linear regression analysis and 
Spearman’s rank correlation coefficients to determine 
interrelationships between parameters.  P-values < 0.05 
were accepted as significant.  All statistical analyses 
were performed with Excel (Microsoft) and EZR 
(Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan),  which is a graphical user interface for 
R (The R Foundation for Statistical Computing,  
Vienna,  Austria).  More precisely,  it is a modified ver-
sion of R commander (2.3-0) designed to add statistical 
functions that are frequently used in biostatistics [14].
Results
Backgrounds of patients in whom serum PCT levels 
were measured. The patients in whom serum PCT 
levels were measured were classified by disease category 
based on a previous report [15] as follows: (1) bacterial 
infection (Bacterial),  (2) non-bacterial infection (Non-
bacterial),  (3) nonspecific inflammation (NSI),  (4) 
neoplasm (Neoplasm),  (5) connective tissue disease 
(CTD),  (6) drug-induced (Drug),  and (7) Unidentified 
cases (Fig. 1).  The numbers (percentages) of patients in 
the categories were 68 (20.5%) for Bacterial,  24 (7.2%) 
for Non-bacterial,  69 (20.8%) for NSI,  33 (9.9%) for 
Neoplasm,  28 (8.4%) for CTD,  12 (3.6%) for Drug,  
and 98 (29.5%) for Unidentified.  The ratios of males to 
females were similar among the 7 disease groups,  
though females were slightly dominant in the NSI and 
Drug groups.
Characteristics of disease categories of the patients.
Table 1 shows the details for each disease category.  The 
Bacterial group (n = 68) included 25 cases of bacterial 
pneumonia (37%),  10 cases of deep abscess (15%),  9 
cases of urinary tract infection (13%),  8 cases of skin 
infection (12%),  and 4 cases of bloodstream infection 
(6%).  The Non-bacterial group (n = 24) included 9 cases 
of viral respiratory tract infection (38%),  4 cases of 
fungal infection (17%),  and 2 cases of aseptic meningi-
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Table 1　 Details of disease categories
AOSD, adult-onset Stillʼs disease; CTD, connective tissue disease; CMV, cytomegalovirus; EBV, Epstein-Barr virus; EGPA, eosinophilic 





Urinary tract infection 9
Skin infection 8




















Deep vein thrombosis 5
Adrenal insufficiency lymphadenitis 5




















Fig. 1　 Numbers and gender ratios of patients in the 
disease categories.  Patients were classified into seven 
groups: bacterial infection (Bacterial),  non-bacterial infec-
tion (Non-bacterial),  nonspecific inflammation (NSI),  con-
nective tissue disease (CTD),  Neoplasm,  drug-induced 
(Drug) and Unidentified cases.
tis (8%).  The NSI group (n = 69) included systemic 
diseases dominated by TAFRO syndrome in 8 cases 
(12%),  Castleman’s disease in 6 cases (9%),  deep vein 
thrombosis in 5 cases (7%),  adrenal insufficiency in 5 
cases (7%),  histiocytic necrotizing lymphadenitis in 4 
cases (6%),  pseudo-gout in 4 cases (6%),  and sarcoid-
osis in 3 cases (4%).  In the Neoplasm group (n = 33),  
16 cases of malignant lymphoma (48%) were predomi-
nant.  The CTD group (n = 28) included 6 cases of rheu-
matoid arthritis (21%),  5 cases of eosinophilic granulo-
matous vasculitis (18%),  4 cases of adult-onset Still’s 
disease (14%),  2 cases of autoimmune hepatitis (7%),  
and 2 cases of Behçet’s disease (7%).
Serum PCT levels in the disease categories. The 
serum PCT levels in the disease groups are shown in 
Fig. 2.  As shown in the panel,  the median levels of 
serum PCT were all around 0.1 ng/mL (Bacterial:  
0.14 ng/mL (interquartile range,  0.054-0.42); Non-
bacterial: 0.076 ng/mL (0.048-0.31); NSI: 0.097 ng/
mL (0.051-0.38); Neoplasm: 0.11 ng/mL (0.062-0.17);  
CTD: 0.065 ng/mL (0.048-0.21); Drug: 0.071 ng/mL 
(0.059-0.19); and Unidentified: 0.056 ng/mL (0.039-
0.97)),  but the actual data were highly dispersed in each 
group.  The serum PCT levels in the Bacterial (p < 0.01),  
NSI (p < 0.01) and Neoplasm (p < 0.05) groups were sig-
nificantly higher than the level in the Unidentified group.
Interrelationships of serum levels of PCT and other 
laboratory data. Figure 3 shows the interrelation-
ships between serum PCT levels,  complete blood 
counts (WBC,  hemoglobin,  and platelet counts),  and 
serum CRP levels.  The serum PCT level showed signifi-
cantly positive correlations with the WBC count and 
serum CRP level but had negative correlations with the 
hemoglobin concentration and platelet count.  The cor-
relation of the serum PCT level with the serum CRP 
level was stronger (rho = 0.62,  p < 0.01) than the correla-
tions of the serum PCT level with the WBC count 
(rho = 0.31,  p < 0.01),  hemoglobin level (rho = −0.36,  
p < 0.01),  and platelet count (rho = −0.16,  p < 0.01).  
Figure 4 shows the correlations of the serum PCT level 
with the levels of the other markers including the serum 
levels of albumin,  ferritin,  and sIL-2R and the plasma 
level of D-dimer,  all of which are involved in various 
inflammatory states.  It was shown that the serum PCT 
level had a significant negative correlation with serum 
albumin (rho = −0.52,  p < 0.01) and weakly positive cor-
relations with the serum level of ferritin (rho = 0.22,  
p < 0.01) and the plasma D-dimer level (rho = 0.32,  
p < 0.01).  It was notable that the serum level of PCT was 
highly correlated with the serum level of sIL-2R 
(rho = 0.69,  p < 0.01).
Serum sIL-2R levels in the disease categories. The 
serum sIL-2R levels in the disease groups are shown in 
Fig. 5.  The median values were 602 ng/ml (interquartile 
range,  452-865) in the Bacterial group,  1,136.5 ng/ml 
(790-1,485) in the Non-bacterial group,  1,096 ng/ml 
(549-1,737) in the NSI group,  846.5 ng/ml (573-5,780) 
in the Neoplasm group,  1,115.5 ng/ml (504-1,844) in 
the CTD group,  1,425 ng/ml (519-3,429) in the Drug 
group,  and 485 ng/ml (345-961) in the Unidentified 
















































Fig. 2　 Distribution of serum procalci-
tonin (PCT) levels in the disease cate-
gories.  The panel shows the median 
levels of serum PCT in the disease 
categories listed in the legend of Fig.1.  
The upper horizontal line,  lower horizon-
tal line,  and horizontal bar of the box 
indicate the 75th percentile,  25th per-
centile,  and median,  respectively.  The 
horizontal bars outside the box are the 
maximum and minimum values within 
1.5 times the interquartile range.  Data 
were analyzed by the Kruskal-Wallis 
test,  and when a significant effect was 
observed,  subsequent comparisons were 
conducted.  ＊p<0.05 and ＊＊p<0.01 
vs. the Unidentified group.
group.  There were no significant differences in the 
serum sIL-2R levels among the disease category groups.
Discussion
In the present study,  we determined the clinical 
diagnostic significance of serum PCT levels by compar-
ing the PCT levels with the levels of other inflammatory 
markers.  The serum PCT levels in patients with bacte-
rial infections were higher than those in the NSI and 
neoplastic diseases groups,  in which the serum PCT 
levels were positively correlated with the WBC counts,  
serum levels of CRP and sIL-2R,  and plasma D-dimer 
level and were negatively correlated with the hemoglo-
bin level,  platelet count,  and serum albumin level.  It is 
notable that the serum level of PCT showed a positive 
correlation with the serum level of sIL-2R,  although the 
serum level of sIL-2R was not significantly different 
among the disease categories,  suggesting that an 
increased PCT level may indicate inflammatory status as 
well as neoplastic status in the diagnostic process for 
various inflammatory disorders.
In the present study,  patients in whom serum PCT 
levels were measured were classified into seven groups 
on the basis of our previous study [13].  Compared with 
that study,  which was conducted in 174 patients with 
FUO in general medicine department,  and which 
included bacterial (21.6%),  non-bacterial (33.1%),  NSI 
(9.5%),  Neoplasm (3.4%),  CTD (4.05%),  Drug-
induced (4.05%),  and Unidentified (24.3%) groups 
[13],  the subjects in the present study included a 
smaller proportion of subjects in the Non-bacterial 
group and larger proportions of subjects in the NSI,  
Neoplasm,  and CTD groups.  In the clinical setting of 
















































































Fig. 3　 Interrelationships between serum levels of procalcitonin (PCT) and blood cell counts or CRP.  Correlations between serum PCT 
levels and biomarkers including white blood cell (WBC) and platelet counts,  hemoglobin concentration,  and serum CRP levels were statis-
tically analyzed by linear regression analysis.  ＊＊p<0.01 and ＊p<0.05,  statistically significant correlations between the indicated factors.















































































































Fig. 4　 Correlations of serum levels of procalcitonin (PCT) with other inflammatory and coagulatory markers.  Correlations between serum 
PCT and other biomarkers,  including albumin,  ferritin,  D-dimer,  and soluble interleukin-2 receptor (sIL-2R),  were statistically analyzed by 
linear regression analysis.  ＊＊p<0.01 and ＊p<0.05,  statistically significant correlations between the indicated factors.
Fig. 5　 Distribution of serum soluble 
interleukin 2 receptor (sIL-2R) levels in 
the disease categories.  The panel shows 
the median levels of serum sIL-2R in the 
disease categories listed in the legend 
of Fig.1.  The lines and dots of the graph 
represent the parameters described in 
the legend of Fig.2.  Data were analyzed 
by the Kruskal-Wallis test.
general practice,  PCT measurements are likely to be 
performed mainly in difficult cases to determine the 
cause of inflammation.  Although the mean serum lev-
els of PCT tended to be higher in patients with bacterial 
infections in the present study,  the median levels of 
serum PCT showed no specific trends among the 
Bacterial (0.14 ng/mL),  Neoplasm (0.11 ng/mL),  and 
NSI (0.97 ng/mL) groups,  with a large dispersion of 
values among cases.
Therefore,  in order to determine the effectiveness of 
serum level of PCT as a marker for various inflamma-
tory diseases,  the relationships of the serum levels of 
PCT with various laboratory parameters were further 
analyzed.  It was found that WBC,  the serum levels of 
CRP and ferritin,  and the plasma level of D-dimer were 
positively correlated with the serum level of PCT,  sug-
gesting that the increases in inflammatory biomarkers 
are mutually associated.  On the other hand,  the hemo-
globin concentration and serum PCT level showed a 
negative correlation,  possibly indicating hematopoietic 
suppression in bone marrow due to chronic systemic 
inflammation [16].  The results showing a strongly neg-
ative correlation between serum PCT and albumin lev-
els also suggest that albumin production in the liver can 
be impaired due to prolonged inflammation [17].
A novel finding of this study was that the serum 
PCT level had a stronger positive correlation with the 
serum level of sIL-2R than with other inflammatory 
markers.  In general,  serum PCT levels tend to be ele-
vated in cases of bacterial infection and sepsis,  while 
serum sIL-2R levels are increased in cases of malignant 
lymphoma,  leukemia,  and hemophagocytic syndrome 
[2 , 18 , 19].  Therefore,  in addition to infectious condi-
tions,  our findings suggest that the serum PCT level 
may be elevated in serious illnesses which increase 
serum sIL-2R level,  including malignant lymphoma.  
Serum PCT levels can also be elevated in cases of severe 
burns and surgical invasions [11 , 20].  In this regard,  
several studies have shown that elevated serum sIL-2R 
is effective as an indicator of bacterial infection and sep-
sis and that bacterial infection and sepsis can be 
detected more precisely or with greater sensitivity by 
sIL-2R examination than by PCT examination in some 
situations [21-23].  In contrast,  it has also been reported 
that the serum levels of PCT and sIL-2R are indepen-
dent markers for the detection of infections and that 
interpreting each of the biomarkers needs to be consid-
ered on a case-by-case basis [24].
The existence of a correlation between the serum 
levels of PCT and sIL-2R suggests that cases with ele-
vated serum PCT levels should be differentiated from 
diseases showing high sIL-2R levels,  such as malignant 
lymphoma.  It is of interest that,  in the present study,  
there was no significant difference in serum sIL-2R lev-
els among the disease categories,  and the serum level of 
PCT was correlated with the serum level of sIL-2R even 
in patients in groups other than the Bacterial group,  
such as patients with nonspecific inflammatory diseases 
(rho = 0.68,  p < 0.01; n = 27),  patients in the Neoplasm 
group (rho=0.88,  p < 0.01; n = 12),  and patients in the 
CTD group (rho = 0.75,  p < 0.01; n = 18).  Although 
cases of elevated sIL-2R may be associated with bacte-
rial infections,  the levels of serum PCT and sIL-2R are 
likely to be at least somewhat related in patients with 
non-bacterial inflammatory conditions,  since positive 
correlations between PCT and sIL-2R were observed 
even in groups other than the Bacterial group.  Thus,  it 
is necessary to consider various possible inflammatory 
conditions in cases with elevated serum levels of PCT.  
On the other hand,  it is also important to consider 
latent bacterial infections,  malignancies,  collagen dis-
eases,  and other inflammatory diseases in cases with 
elevated serum levels of sIL-2R.  In general clinical 
practice,  elevated serum PCT levels correlate with ele-
vated sIL-2R and may suggest not only a bacterial 
inflammatory state,  but also a non-infectious inflam-
matory state.
Limitations of this study should be noted.  This study 
was performed retrospectively at a single center of a 
general medicine department with a relatively small 
number of patients.  To clarify the precise interactions 
between biochemical markers,  a prospective,  multi- 
center study using age-,  gender- and disease-matched 
cohorts will be needed.  Nevertheless,  our results 
uncovered a new clinical utility of serum PCT measured 
in the process of diagnosing inflammatory disorders.  
Increased serum PCT levels measured in patients with 
fever in a general clinical practice setting may indicate 
not only an inflammatory state with bacterial origins but 
also non-infectious inflammation.
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